<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497313</url>
  </required_header>
  <id_info>
    <org_study_id>H-15007280</org_study_id>
    <nct_id>NCT02497313</nct_id>
  </id_info>
  <brief_title>Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating evidence suggests that bile acids in our intestines may constitute essential
      components in the complex mechanisms regulating gut hormone secretion and glucose
      homeostasis. Thus, it is likely that modification of the enterohepatic circulation of bile
      acids can lead to changes in gut hormone secretion and consequently affect glucose
      homeostasis.

      The current study is a human interventional randomized controlled cross-over study including
      four study days for each participant. Metformin will be applied as a tool to reduce bile acid
      reuptake in the small intestine; thereby increasing bile acid concentration in the more
      distal parts of the gut where GLP-1-secreting L cell are abundant. Interestingly, metformin
      has been shown to reduce the active reabsorption of bile acids in the ileum and cause
      increased faecal elimination of bile acids. Clinical data has suggested that metformin causes
      an increase in the postprandial secretion of GLP-1 in humans including patients with type 2
      diabetes. Intravenous infusion of cholecystokinin will be used to elicit gallbladder
      contraction and emptying. The aim is to examine how (and if) modification of bile acid
      reabsorption can influence postprandial glucagon-like peptide-1 (GLP-1) secretion and glucose
      homeostasis in patients with type 2 diabetes.

      The investigators hypothesize that higher luminal concentrations of bile acids in the distal
      gut will elicit changes in gut hormone secretion. The current study will help to clarify this
      hypothesis and improve our general understanding of the association between bile acid
      circulation and signalling, gut hormone secretion and glucose metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1-4</time_frame>
    <description>Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responses of various other gut hormones: Incremental and total area under the Concentration-Time Curve</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1-4</time_frame>
    <description>Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood analysis of paracetamol as an assessment of gastric emptying</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1-4</time_frame>
    <description>Assessment of gastric emptying</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect calorimetry: Basal metabolic rate</measure>
    <time_frame>-30 min to 240 min</time_frame>
    <description>Basal metabolic rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder volume as assessed by Ultrasound measurements</measure>
    <time_frame>-30 min to 240 min</time_frame>
    <description>Gallbladder volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite as assessed by Visual analog scale score</measure>
    <time_frame>-30 min to 240 min</time_frame>
    <description>Appetite</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Cholecystokinin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ingestion of metformin combined with intravenous infusion of isotonic saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin+Cholecystokinin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <arm_group_label>Placebo+Placebo</arm_group_label>
    <arm_group_label>Metformin+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin placebo</intervention_name>
    <arm_group_label>Placebo+Placebo</arm_group_label>
    <arm_group_label>Placebo+Cholecystokinin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecystokinin</intervention_name>
    <arm_group_label>Placebo+Cholecystokinin</arm_group_label>
    <arm_group_label>Metformin+Cholecystokinin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin+Placebo</arm_group_label>
    <arm_group_label>Metformin+Cholecystokinin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for at least 3 months (diagnosed according to the criteria of the
             World Health Organization (WHO))

          -  Men and postmenopausal women

          -  Metformin applied as the only anti-diabetic drug

          -  Caucasian ethnicity

          -  Normal haemoglobin

          -  BMI &gt;23 kg/m2 and &lt;35 kg/m2

          -  Informed and written consent

        Exclusion Criteria:

          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase
             (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder

          -  Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major
             intra-abdominal surgery

          -  Nephropathy (serum creatinine &gt;150 µM and/or albuminuria)

          -  Hypo- and hyperthyroidism

          -  Hypo- and hypercalcaemia

          -  Hypo- and hyperphosphataemia

          -  Active or recent malignant disease

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Treatment with oral anticoagulants

          -  Any treatment or condition requiring acute or sub-acute medical or surgical
             intervention

          -  Any condition considered incompatible with participation by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Brønden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhD-student</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Diabetes Research, Herlev-Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Andreas Brønden</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Cholecystokinin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

